Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Viking Experimental Obesity Pill Shows Promise in Early Study
Viking Therapeutics Inc. said higher doses of its experimental pill increased patients’ weight loss beyond earlier formulations, strengthening its case to eventually compete with blockbuster shots from Novo Nordisk A/S and Eli Lilly & Co.
AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class. The Phase I trial - which had 72 participants - was designed to assess the safety and tolerability of the pill,
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 amo
Viking Obesity Pill Data Shows Promise Against Shots
Yes, a Viking drug So it's a dual agonist of oral gel or an oral drug, GLP one and GLP essentially targeting two receptors. And yeah, I guess it was one of the most eagerly awaited kind of data set that was conference on that.
Quartz on MSN1d
A new weight loss pill outperformed Novo Nordisk's version
Pills are displayed with open pill bottles on top of a white counter top in the kitchen.Viking Therapeutics (VKTX) released ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
FierceBiotech1d
Viking oral obesity med posts 6.8% weight loss for highest dose
The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...
AstraZeneca says experimental obesity pill safe in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
bovnews19d
Viking Therapeutics Inc (VKTX) Stock: More Strategic Than Meets the Eye
On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $65.85 which represents a slight increase of $0.47 or 0.72% from the prior close of $65.38. The stock opened ...
Zacks.com on MSN20d
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
Viking Therapeutics, Inc. (VKTX) closed at $65.85 in the latest trading session, marking a +0.72% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. On the ...
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...
The Motley Fool19d
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
That's more than enough to cover its operating cash burn, which over the trailing 12 months has totaled just under $72 million. Even if its rate of cash burn accelerates, Viking looks to have ...
Viking Therapeutics: Lots Of Positives
Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment.